Advances in Orally Disintegrating Tablets (ODTs): Formulation Strategies and Future Prospects
Abstract
Objective: This review critically evaluates recent advances in orally disintegrating tablet (ODT) technologies, with emphasis on innovative formulation and manufacturing strategies developed to overcome the limitations of conventional ODT approaches, particularly for poorly soluble and high-dose drug substances.
Data Sources: A comprehensive narrative literature review was conducted using PubMed, Scopus, and ScienceDirect, supplemented by relevant articles identified from Google Scholar, reference lists of selected publications, and other authoritative pharmaceutical sources. Relevant pharmaceutical literature and regulatory guidelines were reviewed, with a primary emphasis on emerging technologies published between 2015 and 2026.
Summary Of Contents: While ODTs have significantly improved patient compliance, especially among pediatric and geriatric populations, formulation challenges persist for Biopharmaceutics Classification System (BCS) Class II and IV drugs and high-dose active pharmaceutical ingredients. This review explores emerging technologies such as fused deposition modeling (FDM), selective laser sintering (SLS), and binder jetting 3D printing, which enable enhanced control over tablet architecture, porosity, and disintegration behavior. Additionally, the incorporation of nanotechnology-driven systems, including nanocrystals and spray-dried amorphous solid dispersions, has shown promise in improving drug dissolution and oral bioavailability. Critical quality attributes, including disintegration time, mechanical strength, and moisture sensitivity, are evaluated, with particular attention to formulation performance under tropical climatic conditions (ICH Zone IVb). Prospects emphasize a shift toward point-of-care personalized medicine and the potential for mucoadhesive ODTs in biologics delivery, while identifying current barriers to large-scale commercial adoption and the evolving regulatory landscape for biowaivers.
Conclusion: The convergence of advanced manufacturing technologies and rational formulation design positions next-generation ODTs as a promising platform for patient-centric drug delivery, while emphasizing the need for scalable, robust, and climate-resilient manufacturing strategies.
Keywords: Orally disintegrating tablets, 3D printing, nanotechnology, bioavailability, patient compliance, BCS classification.
Keywords:
Orally disintegrating tablets, 3D printing, nanotechnology, bioavailability, patient compliance, BCS classificationDOI
https://doi.org/10.22270/jddt.v16i3.7603References
1. Chinwala M. Recent formulation advances and therapeutic usefulness of orally disintegrating tablets (ODTs). Pharm J Pharm Educ Pract. 2020;8(4):186. https://doi.org/10.3390/pharmacy8040186 PMid:33050437 PMCid:PMC7712969
2. Ghourichay MP, Kiaie SH, Nokhodchi A, Javadzadeh Y. Formulation and quality control of orally disintegrating tablets (ODTs): Recent advances and perspectives. BioMed Res Int. 2021;2021:6618934. https://doi.org/10.1155/2021/6618934 PMid:34977245 PMCid:PMC8719989
3. Khadivi Y, Monajjemzadeh F. Advancement in the formulation and development of orally disintegrating tablets: Innovation, challenges, and future perspective. J Drug Deliv Sci Technol. 2025;108:106965. https://doi.org/10.1016/j.jddst.2025.106965
4. Zhang Y, Liu X, Huang Y, Sun L, Zhang L. Paediatric orally disintegrating tablets: Overlooking the future from multiple aspects. Eur J Pharm Biopharm. 2026;219:114960. https://doi.org/10.1016/j.ejpb.2025.114960 PMid:41365425
5. Ono A, Tomono T, Ogihara T, Terada K, Sugano K. Investigation of biopharmaceutical drug properties suitable for orally disintegrating tablets. ADMET DMPK. 2016;4(4):335-344. https://doi.org/10.5599/admet.4.4.338
6. Precedence Research. Orally disintegrating tablet market size to surpass USD 31.80 billion by 2034. Ottawa: Precedence Research; 2024.
7. Straits Research. Orally disintegrating tablet market size and demand by 2033. Pune: Straits Research; 2024.
8. Market.us. Orally disintegrating tablet market report. Pune: Market.us; 2024.
9. Liao YJ, Liang YJ. Beyond dysphagia in Parkinson's disease: Three-dimensional printing of orally disintegrating tablets for optimized treatment. Pharmaceuticals. 2025;18(12):1886. https://doi.org/10.3390/ph18121886 PMid:41471375 PMCid:PMC12735962
10. U.S. Food and Drug Administration. Guidance for Industry: Orally Disintegrating Tablets. Silver Spring (MD): CDER; 2008.
11. International Council for Harmonisation. Biopharmaceutics Classification System-Based Biowaivers (ICH M9). Geneva: ICH; 2019.
12. Alsaidan I, Alanazi FK, Badran MM, et al. Formulation and evaluation of proliposomal tablets of diclofenac sodium. Drug Invent Today. 2022;18(3):345-352.
13. Fouad SA, Malaak FA, El-Nabarawi MA, Zeid KA. Development of orally disintegrating tablets containing solid dispersion of a poorly soluble drug. PLoS One. 2020;15(12):e0244646. https://doi.org/10.1371/journal.pone.0244646 PMid:33382789 PMCid:PMC7774920
14. Alshora DH, Ibrahim MA, Alanazi F, et al. In vitro and in vivo evaluation of ibuprofen nanosuspensions for enhanced oral bioavailability. Med Princ Pract. 2021;30(4):361-370. https://doi.org/10.1159/000516299 PMid:33823524 PMCid:PMC8436653
15. Bowles BJ, Dziemidowicz K, Lopez FL, et al. Co-processed excipients for dispersible tablets: Part I. AAPS PharmSciTech. 2018;19(6):2598-2609. https://doi.org/10.1208/s12249-018-1090-4 PMid:29916193
16. Coetzee R, Hamman J, Steenekamp J, Hamman H. Functional attributes of co-processed excipients in orally disintegrating tablets. Pharm Dev Technol. 2025;30(10):1-10. https://doi.org/10.1080/10837450.2025.2584127 PMid:41190702
17. Sahu Y, Sahu B, Kori ML. Comparative study of synthetic and natural superdisintegrants in orally disintegrating tablets. J Drug Deliv Ther. 2025;15(12):88-102. https://doi.org/10.22270/jddt.v15i12.7496
18. Nabila N, Karo-Karo SU. Exploring natural disintegrants as alternative excipients in fast disintegrating tablets. Int J Sci Res Arch. 2024;13(2):3296-3305. https://doi.org/10.30574/ijsra.2024.13.2.2530
19. Drašković M, Medarević D, Aleksić I, Parojčić J. Taste-masking effectiveness of Eudragit E PO in orally disintegrating tablets. Drug Dev Ind Pharm. 2017;43(5):723-731. https://doi.org/10.1080/03639045.2016.1220572 PMid:27494420
20. Kadota K, Terada H, Fujimoto A, et al. Development of taste-masked memantine orally disintegrating tablets. Int J Pharm. 2021;604:120725. https://doi.org/10.1016/j.ijpharm.2021.120725 PMid:34029663
21. Matsui R, Uchida S, Namiki N. Taste masking strategies for propiverine hydrochloride orally disintegrating tablets. Biol Pharm Bull. 2015;38(1):17-22. https://doi.org/10.1248/bpb.b14-00467 PMid:25744453
22. International Council for Harmonisation. Stability Testing of New Drug Substances and Products Q1A(R2). Geneva: ICH; 2003.
23. Vanbillemont B, Everaert H, De Beer T. Characterization and stability of lyophilized orally disintegrating tablets. Int J Pharm. 2020;579:119153. https://doi.org/10.1016/j.ijpharm.2020.119153 PMid:32084575
24. Al-Zoubi N, Gharaibeh S, Aljaberi A, Nikolakakis I. Spray drying as a particle engineering technique for direct compression. Processes. 2021;9(2):267. https://doi.org/10.3390/pr9020267
25. Woyna-Orlewicz K, Brniak W, Tatara W, et al. Impact of co-processed excipients on properties of orally disintegrating tablets. Pharm Res. 2023;40(12):2947-2962. https://doi.org/10.1007/s11095-023-03605-x PMid:37726407 PMCid:PMC10746752
26. Kozakiewicz-Latała M, et al. Three-dimensional printed solid oral dosage forms: A review. Expert Opin Drug Deliv. 2023;20(12):1-15.
27. Allahham N, Fina F, Marcuta C, et al. Selective laser sintering 3D printing of ondansetron orally disintegrating printlets. Pharmaceutics. 2020;12(6):536. https://doi.org/10.3390/pharmaceutics12020110 PMid:32019101 PMCid:PMC7076455
28. Auel F, Soh JLM, Boetker JP, Rantanen J. Three-dimensional printing of pharmaceutical dosage forms. Int J Pharm. 2024;654:123985.
29. Karalia D, Siamidi A, Karalis V, Vlachou M. Three-dimensional printed oral dosage forms: Advances and challenges. Pharmaceutics. 2021;13(9):1401. https://doi.org/10.3390/pharmaceutics13091401 PMid:34575475 PMCid:PMC8467731
30. Elsonbaty A, et al. Fused deposition modeling technology in three-dimensional printing: Pharmaceutical applications. J Eng Res Rep. 2024;26(11):304-312. https://doi.org/10.9734/jerr/2024/v26i111332
31. Gueche Y, Sanchez-Ballester NM, Cailleaux S, et al. Selective laser sintering for solid oral dosage forms. Pharmaceutics. 2021;13(8):1212. https://doi.org/10.3390/pharmaceutics13081212 PMid:34452173 PMCid:PMC8399326
32. Awad A, Trenfield SJ, Goyanes A, Gaisford S, Basit AW. Three-dimensional printing of pharmaceuticals: A review. Trends Pharmacol Sci. 2020;41(6):397-409.
33. Scoutaris N, Ross S, Douroumis D. Inkjet printing in pharmaceutical manufacturing. Pharm Res. 2020;37(7):138.
34. Trenfield SJ, Awad A, Buanz A, et al. Binder jet three-dimensional printing of pharmaceutical solid dosage forms. Int J Pharm. 2021;599:120435.
35. Huanbutta K, Sangnim T. Practical aspects of pharmaceutical three-dimensional printing. Pharmaceutics. 2023;15(7):1877. https://doi.org/10.3390/pharmaceutics15071877 PMid:37514063 PMCid:PMC10385973
36. Yee KM, Mohamad N, Kee PE, et al. Recent advances in orally disintegrating tablets. Drug Deliv Lett. 2024;14(3):275-285. https://doi.org/10.2174/0122103031291909240317162755
37. Lopez-Vidal L, Real JP, Andrés Real D, et al. Three-dimensional printed nanocrystals. In: Shahzad Y, editor. Drug Delivery Using Nanomaterials. London: IntechOpen; 2022. p.105-129.
38. Kumar R, Singh A, Salwan R, et al. Review on solid dispersion systems for solubility enhancement. GSC Biol Pharm Sci. 2023;22(1):114-121. https://doi.org/10.4103/jpbs.jpbs_432_22 PMid:37654356 PMCid:PMC10466630
39. Mohammed KG, et al. Pharmaceutical three-dimensional printing in Africa: Opportunities and challenges. Int J Pharm 2025; 671:124842.
40. Trenfield SJ. Quality control of three-dimensional printed pharmaceuticals [PhD thesis]. London: University College London; 2025.
41. Mishra P, et al. Three-dimensional printing in pharmaceutical manufacturing. World J Pharm Res. 2024;13(9):773-780.
42. Wang J, et al. Personalized orally disintegrating tablets with complex internal structures. Int J Pharm. 2025;673:125371. https://doi.org/10.1016/j.ijpharm.2025.125371 PMid:39971168
43. Tiboni M, et al. Fabricating orally disintegrating tablets without disintegrants. Pharmaceutics. 2022;14(4):435.
44. Gokulakrishnan R, et al. Review of orodispersible tablets: Formulation and evaluation. J Drug Deliv Ther. 2025;15(12):246-253. https://doi.org/10.22270/jddt.v15i12.7432
45. World Health Organization. Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. Geneva: WHO; 2018.
46. Ettedgui J, et al. Stability challenges of solid dosage forms in tropical climates. Int J Pharm. 2022;615:121484.
47. Wu Y, et al. Stability of pharmaceutical dosage forms in hot and humid climates. AAPS PharmSciTech. 2020;21(1):1-12.
48. Trenfield SJ, et al. Additive manufacturing for pharmaceuticals: Technology and regulatory considerations. Adv Drug Deliv Rev. 2018;132:156-172.
49. National Agency for Food and Drug Administration and Control. Guidelines for Registration of Locally Manufactured Drug Products in Nigeria. Abuja: NAFDAC; 2023.
50. European Pharmacopoeia Commission. European Pharmacopoeia. 10th ed. Strasbourg: Council of Europe; 2020.
51. International Council for Harmonisation. Pharmaceutical Development Q8(R2). Geneva: ICH; 2009.
52. Tan DK, Maniruzzaman M, Nokhodchi A. Pharmaceutical applications of fused deposition modeling three-dimensional printing. Pharmaceutics. 2020;12(2):119.
53. Okunlola A, Odeku OA. Modified Dioscorea rotundata starch as a tablet disintegrant. J Drug Deliv Ther. 2021;11(1):45-52.
54. Builders PF, et al. Evaluation of natural excipients in tablet formulation. AAPS PharmSciTech. 2016;17(5):1043-1052.
Published
Abstract Display: 214 
PDF Downloads: 241 PDF Downloads: 52 How to Cite
Issue
Section
Copyright (c) 2026 Joseph Eze, Mercy Agu, Nnaemeka Okoli , Francis okoli, Joshua Agbo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.